BioSpace News Archive

AOBiome Therapeutics, Inc. (“AOBiome”) today announces that The Lancet’s eClinicalMedicine, a peer-reviewed medical journal, has published a report describing the Company’s Phase 2b clinical data for its B244 treatment for mild-to-moderate atopic dermatitis and moderate-to-severe pruritus.

The Insight Partners published latest research report on “Pharmaceutical Excipients Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Clinical Indication, Functionality, Application, End User”,

The Insight Partners published latest research report on “High Throughput Screening Market Revenue Report, Trends, Growth & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Service, Technology, Application, End User”

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-severe active ulcerative colitis (UC).

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou (PRIG) announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) TC Cream to launch a U.S.-based multicenter Phase III clinical study to treat patients with psoriasis vulgaris, following a previously completed Phase IIb trial (NCT03372811).

Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficiency disorder.

Sun Genomics continues to strategically expand its brand and clinical offerings with the appointment of Will Hankee as vice president of sales and business development.

Intelligent Bio Solutions Inc. today announced plans to add the potent synthetic opioid drug, fentanyl, and fentanyl-adulterated street drugs, to the panel of substances detected by its lab-based confirmation testing using fingertip sweat collected by its proprietary Intelligent Fingerprinting Drug Screening System.

Soligenix, Inc. announced today that the European Patent Office has granted a patent entitled “Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis”.

Aviceda Therapeutics today announced the appointment of Patrick Johnson to its board of directors.